Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s Positive 3Q Results

854

Dallas, Texas 11/04/2013 (Financialstrend) – Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported $1.54B in total revenue for the Q3, which was a 74% rise from the same quarter in 2012.Products sales amounted to a total of $1.5B, which was, up from $852.7M in the same quarter in 2012. Developed markets revenue amounted to $1.14B, a 77% rise from the Q3 of 2012. This was primarily attributed to the Bausch & Lomb acquisition.

Emerging markets revenue amounted to a total of $399 million, a 68% rise from the same quarter in 2012. This also was a result of the Bausch & Lomb acquisition. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported a net-loss of $973M for the Q3 , a loss of $2.92/share, due to one-time impairment-charges, settlement of the contract dispute & restructuring, integration & other charges  which mainly stemmed from the Bausch & Lomb  acquisition.

R&D costs totaled $49M which was a rise from $19M in comparison to the 2012 Q3.

For the 9-month period that ended 30 Sept, revenue totaled $3.7B which was up from $2.6B in the same quarter of 2012. Product-sales totaled $3.6B, up from $2.3B in the previous year.

Friday’s trading

In Friday’s trading, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rose by 5.18%. The opening price of the shares was $106.00, which climbed to an intraday high of $111.42 and dipped to a close of $111.20. Approximately 2.53 million shares were traded on Friday while an average volume of 1.30 million shares were traded over a 30 day period. The 52-week low of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares is $52.50 and its 52-week high is $115.39. The company has a market capitalization of $37.01 billion.

About the company

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was previously Biovail Corporation. It is a multi-national, specialty-pharmaceutical company that is involved in developing, manufacturing and marketing a variety of pharmaceutical products.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.